Pitavastatin: an overview of the LIVES study

References

• Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis 216, 258–265 (2011).
   Google Scholar
• Duff CJ, Hooper NM. PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin. Ther. Targets. 15, 157–168 (2011).
   Google Scholar
• Huffman MD, Bhatnagar D. Novel treatments for cardiovascular disease prevention. Cardiovasc. Ther. 20(6), 741–754 (2011).
   Google Scholar
• Kourounakis AP, Katselou MG, Matralis AN, Ladopoulou EM, Bavavea E. Squalene synthase inhibitors: an update on the search for new antihyperlipidemic and antiatherosclerotic agents. Curr. Med. Chem. 18(29), 4418–4439 (2011).
   Google Scholar
• Warrington S, Nagakawa S, Hounslow N. Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men. Clin. Drug Investig. 31, 735–743 (2011).
   Google Scholar
• Kurihara Y, Douzono T, Kawakita K, Nagasaka Y. A large-scale, long-term, prospective postmarketing surveillance of pitavastatin (LIVALO Tablet) – LIVALO Effectiveness and Safety (LIVES) Study. Jpn Pharmacol. Ther. 36, 709–731 (2008).
   Google Scholar
• Hounslow N. Pitavastatin and renal impairment: an analysis of the latest data from the LIVES Study. Presented at: European Society of Cardiology Congress 2010. Stockholm, Sweden, 28 August–1 September 2010.
   Google Scholar
• Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J. Atheroscler. Thromb. 16, 654–661 (2009).
   Google Scholar
• Hounslow N. Pitavastatin provides long-term improvements in HDL-cholesterol in a range of patients with dyslipidaemia:results from a phase III study programme. Presented at: The 79th European Atherosclerosis Society Congress. Gothenburg, Sweden, 26–29 June 2011 (Abstract).
   Google Scholar
• Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103, 357–362 (2001).
   Google Scholar
• Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J. Am. Coll. Cardiol. 55, 1209–1216 (2010).
   Google Scholar
• Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375, 735–742 (2010).
   Google Scholar
• Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group; Armitage J, Bowman L et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376, 1658–1669 (2010).
   Google Scholar
• Preiss D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305, 2556–2564 (2011).
   Google Scholar
• Waters DD, Ho JE, DeMicco DA et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J. Am. Coll. Cardiol. 57, 1535–1545 (2011).
   Google Scholar
• Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin. Pharmacother. 11, 817–828 (2010).
   Google Scholar
• Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139, 137–147 (2003).
   Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42, 1050–1065 (2003).
   Google Scholar
• Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305 (2004).
   Google Scholar
• Kimura K, Shimano H, Yokote K, Urashima M, Teramoto T. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J. Atheroscler. Thromb. 17, 601–609 (2010).
   Google Scholar
• Teramoto T, Sasaki J, Ueshima H et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J. Atheroscler. Thromb. 14, 45–50 (2007).
   Google Scholar